

## Press Release

**Strides Shasun Reports Robust Q4 FY16 and FY16 Results  
Pharma Delivers Strong Operating Margins, R&D Gains Momentum  
Q4 FY16 Pharma Revenues INR 10,036 Mn, EBITDA at INR 2,016 Mn (20%)  
FY16 Pharma Revenues INR 31,776 Mn, EBITDA at INR 5,814 Mn (18%)  
Board Recommends Dividend of Rs.4 per share (40%)**

**Bengaluru, May 16, 2016:** Strides Shasun (BSE: 532531, NSE: STAR) today announced its Q4 FY16 and FY 2016 results.

### Pharma Performance Highlights – Q4 FY16 & FY16

#### Global Pharma

INR Mn

	Q4 FY15	Q4 FY16	YoY Growth %	FY15	FY16	YoY Growth %
Revenues	7,027	<b>10,036</b>	43%	25,468	<b>31,776</b>	25%
EBITDA	1,255	<b>2,016</b>	61%	4,008	<b>5,814</b>	45%
EBITDA %	18%	<b>20%</b>	220bps	16%	<b>18%</b>	260bps
Adj Pharma EPS*		<b>13.25</b>			<b>32.81</b>	

\*Excluding Merger & due diligence costs of INR 87 Mn, one time write off INR 65 Mn and Biotech INR 44 Mn for Q4 FY16

\*Excluding Merger & due diligence costs of INR 221 Mn, one time write off INR 65 Mn and Biotech INR 242 Mn for FY16

\*Exchange impact of prior year 168 Mn on account of Shasun merger

\*Q4 FY15 and FY15 numbers have been taken from the press releases and re-aligned to the current year reporting structure for comparative purposes

#### H2 FY 2016 Performance versus Guidance

- Revenues at INR 18,583 Mn in H2 FY16 versus guidance of INR 18,500-20,000 Mn
- EBITDA at INR 3,644 Mn in H2 FY16 versus guidance of INR 3,500 – 3,800 Mn
- EBITDA margin at 20 % in H2 FY16 versus guidance of 19 %
- 10 ANDA filing in H2 FY 16 in line with guidance

**Arun Kumar, Executive Vice Chairman and Managing Director**, stated “We are making steady progress across each of our businesses and are tracking ahead of the execution plan under version 2.0. We closed out fiscal year 2016 on a high note with a milestone quarter and a strong business momentum despite a weak performance from our emerging market operations. We continue to focus on creating synergies by leveraging a fully integrated business model to deliver significant shareholder value.”

**Consolidated Financial & Performance Highlights (Pharma & Biotech) INR Mn**

	Q4 FY15*	Q4 FY16	YoY Growth %	FY15*	FY16	YoY Growth %
Revenues	7,027	<b>10,036</b>	43%	25,468	<b>31,776</b>	25%
EBITDA	1,229	1,968	60%	3,928	5,617	43%
EBITDA %	18%	20%	210bps	15%	18%	230bps
Adj PAT*		<b>1,139</b>			<b>2,468</b>	
Adj EPS*		<b>12.75</b>			<b>29.88</b>	

\*Q4 FY15 and FY15 numbers have been re-aligned to the current year reporting structure for comparative purposes

Detailed Performance highlights for the financial year 2016 is attached as a presentation

## Annexure:

### EBITDA Computation:

	Q4 FY 2016	FY16
SEBI Results	Column 1	Column 5
Profit from ordinary activities before finance cost & Exceptional Items as per SEBI reporting	1,703	4,852
Less: Interest, Dividend income, Gain on sale of securities	204	808
Add : Depreciation and Amortization	469	1,573
Consolidated EBITDA as per press release	1,968	5,617
Add: Biotech R&D Spend	48	197
Global Pharma EBITDA as per press release	2,016	5,814

### About Strides Shasun

Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has global manufacturing foot print with 14 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries Additional information is available at the Company's website at [www.stridesarco.com](http://www.stridesarco.com)

### For further information, please contact:

<p><b><u>Strides</u></b></p> <p>Badree Komandur, Group CFO +91 80 6784 0747</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p>	<p><b><u>PR Consultancy</u></b></p> <p><b>Fortuna PR</b> K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.in</p> <p>K Priya: +91 9535425418 priya@fortunapr.in</p>
---	---